United Therapeutics down 3% over possible delay in Remodulin infusion pump

  • United Therapeutics (NASDAQ:UTHR) was under pressure today, down 3% on light volume, on a possible delay in releasing a programmable infusion pump for Remodulin (treprostinil) users.
  • RBC's Michael Yee says the heightened risk comes from Medtronic's (NYSE:MDT) recall of its SynchroMed II/EL pumps due to a priming bolus issue, which it plans to fix with a software update. A year ago, the FDA rejected Medtronic's marketing application for an implantable pump to deliver Remodulin. The pulmonary arterial hypertension med faces generic competition in 2018 so a delay in offering an implantable pump option would make it more difficult for UTHR to protect sales.
  • Source: Bloomberg

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.